Sensitivity as outcome measure of androgen replacement: the AMS scale
2006

AMS Scale Effectiveness in Measuring Quality of Life in Androgen-Deficient Males

Sample size: 1670 publication Evidence: moderate

Author Information

Author(s): Heinemann Lothar A, Moore Claudia, Dinger Juergen C, Stoehr Diana

Primary Institution: Center for Epidemiology & Health Research Berlin

Hypothesis

The AMS scale can effectively measure treatment effects on quality of life in androgen-deficient males.

Conclusion

The AMS scale effectively measures treatment effects on quality of life across various severity levels of complaints.

Supporting Evidence

  • The AMS scale showed a 30.7% improvement in total score after treatment.
  • Patients with severe symptoms showed a 39% improvement compared to baseline.
  • The AMS scale can predict the physician's opinion on treatment success with over 70% sensitivity and specificity.
  • Age, BMI, and testosterone levels did not significantly affect treatment outcomes.

Takeaway

The AMS scale helps doctors see how well testosterone treatment is working for men with low testosterone, showing improvements in their quality of life.

Methodology

An open post-marketing study was conducted with 1670 androgen-deficient males treated with testosterone gel, using the AMS scale before and after 12 weeks of treatment.

Potential Biases

The study may have bias due to the lack of randomization and potential conflicts of interest from authors affiliated with testosterone product companies.

Limitations

The study did not determine a required sample size and was observational in nature.

Participant Demographics

{"mean_age":56.4,"mean_BMI":26.8,"testosterone_level":2.5}

Statistical Information

P-Value

<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1186/1477-7525-4-23

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication